ADT Aktie

 

BOCA RATON, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT), a provider of smart home and small business security solutions, today announced a $100,000 donation to support All Things Made New, a Dallas-area nonprofit that helps teens and young adults through mentorship, life skills coaching and access to essential resources....

The average daily turnover (ADT) of Hong Kong stocks in April was strong, UOB Kay Hian released a research report saying. The broker expected HKEX (00388.HK) to see a 31% YoY increase in 2Q25 earnings. Although UOB Kay Hian anticipated a slowdown in market activity from recent peak levels, it believed that improving IPO activiti......

ADT, DDI and MHO have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2025....

HIRADO, Japan, June 9, 2025 /PRNewswire/ -- Hirado City in Nagasaki Prefecture has obtained the official certification as "Albergo Diffuso Town" (ADT) for the first time in the world as a local municipality. With the whole town being regarded as one hotel, such functions as lodgings,......

Apollo Management Holdings Gp, LLC - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-06-04...

HKEX (00388.HK) latest disclosed data showed that the average daily turnover (ADT) of the Hong Kong securities market in the first five months of 2025 was HKD242.3 billion, up 120% YoY. The ADT in May was HKD210.3 billion, up 50% YoY.As of the end of May 2025, the total market cap of the Hong Kong securities market reached HKD40......

Investors need to pay close attention to ADT stock based on the movements in the options market lately....

NUBEQA® (darolutamide) is the first and only androgen receptor inhibitor (ARi) to show clinically meaningful delays in deterioration of important patient-relevant health-related quality of life (HRQoL) outcomes for patients with metastatic castration-sensitive prostate cancer (mCSPC) In post-hoc analyses of the Phase III ARANOTE trial, patients treated with NUBEQA plus androgen deprivation therapy (ADT) had an extended time to deterioration in HRQoL, with an additional 5.1 months compared to placebo plus ADT (16.6 months versus 11.5 months; HR 0.76, 95% CI 0.61–0.93) The results will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting WHIPPANY, N.J.--(BUSINESS WIRE)--New post-hoc analyses from the investigational Phase III ARANOTE trial showed a clinically meaningful improvement in health-related quality of life (HRQoL) and delayed pain progression for metastatic castration-sensitive prostate cancer (mCSPC) patients treated with NUBEQA® (darolutamide) plus androgen dep...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival......

Post hoc analyses from the pivotal Phase III ARANOTE trial evaluating health-related quality of life (HRQoL) outcomes with NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) will be presented Additional data include an analysis of the investigational Phase III PEACE III study of the first and only approved targeted alpha emitting radiopharmaceutical, XOFIGO® (radium-223 dichloride), that treats bone metastases in metastatic castration-resistant prostate cancer (mCRPC) Safety and efficacy results for the investigational compound sevabertinib (BAY 2927088) in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) will also be showcased Bayer will also present data from the Phase III OASIS-4 trial conducted outside of the U.S. of the investigational compound elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) caused by adjuvant endocrine therapy Abstracts: 5004 | TPS5131 | 5048 | 5062 | 5007 | 8504 | 508 | 12063 | WHIPPANY, N.J...

Apollo Management Holdings Gp, LLC - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-05-12...

HKEX (00388.HK)'s 1Q25 results were in line with expectations, with net profit growing 37% YoY on the back of a sharp rise in average daily turnover (ADT) and stronger-than-expected net interest margin, according to a research report issued by UOB Kay Hian. Operating expense costs were contained at 7% YOY incline, partially ......

ADT and Yale launch the first Z-Wave smart lock with fingerprint control, integrating seamlessly with ADT+ for smarter, faster, touch-based security....

JP Morgan issued a research report covering HKEX (00388.HK), which delivered strong set of 1Q25 results, given remarkable growth in ADT for securities and derivatives, paired with increased NII. However, looking ahead, JP Morgan expected ADT to normalize. The broker maintained a Neutral rating on HKEX, noting that sustained chan......

29 April 2025   Update on CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer   AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer (mCRPC).   This decision is based on the recommendation of the Independent Data Monitoring Committee (IDMC) following their review of data from a pre-specified...

Investors need to pay close attention to ADT stock based on the movements in the options market lately....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

ADT (ADT) delivered earnings and revenue surprises of 5% and 2.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

ADT Inc (NYSE:ADT) reported first-quarter financial results before the market open on Thursday. Here's a look at the key details from the report. read more...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...